

Data Sheet

Product Information

Catalog Number	BP13326
Product Name	Abemaciclib
Description	LY2835219 is an effective and specific CDK4/6 inhibitor (IC50: 2/10 nM).
Targets&IC50	CDK4:2 nM, CDK6:10 nM
In vitro	LY2835219 reduces cell viability with the IC50 values ranging from 0.5 μ M to 0.7 μ M, inhibits Akt and ERK signaling but not mTOR activation at head and neck squamous cell carcinoma (HNSCC) cells. LY2835219 shows inhibition on A375R1-4, M14R, and SH4R with EC50 values ranging from 0.3 to 0.6 μ M; LY2835219 inhibits the proliferation of the parental A375 and resistant A375RV1 and A375RV2 cells with similar potencies with IC50 values of 395, 260, and 463 nM, respectively. LY2835219 inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells.
In vivo	LY2835219 (45 mg/kg, p.o.) in combination with everolimus causes a cooperative antitumor effect in HNSCC xenograft tumor. LY2835219 (45 or 90 mg/kg, p.o.) shows significant tumor growth inhibition in an A375 xenograft model.
Synonyms	LY2835219, CDK4/6 dual inhibitor
CAS No.	1231929-97-7
Chemical Formula	C27H32F2N8
Molecular Weight	506.606

Solubility	DMSO: 6 mg/mL(11.8 mM)
Storage	Powder: -20°C for 2 years In solvent: -80°C for 1 year
Chemical Structure OR Tested Image	

Purdue Bioscience Inc.

750 50th St, Brooklyn, NY 11220, USA

https://www.purduebio.com

1-877.618.7311

info@purduebio.com

v2 Revision on 12/28/2022